Wiley Corporate Logo

Top Navigation

Simplified Methods for Investigating Deregulation of the Cell Cycle and Apoptosis in Cancer Progression, and the Implications for Anti-Cancer Therapies

About the Webinar

The complexities of cancer research demand diverse approaches that include studies of the critical events that propel the tumor cell and it’s progeny into uncontrolled expansion and invasion. This evolution of normal cells into cancer cells is facilitated by loss of fidelity in the processes that replicate, repair, and segregate the genome, such as the regulation of cell cycle, apoptosis and cell proliferation. Recent advances in our understanding of these critical events suggest molecular mechanisms for cellular transformation, and may help to identify potential targets for improved cancer therapies.

The DNA replication initiation machinery, a component of the cell cycle engine which serves as a relay station connecting signalling networks with DNA synthesis, is a promising target for diagnostic and therapeutic interventions.

In this webinar Dr. Kai Stoeber (Shionogi Ltd.) will introduce methods for studying DNA replication initiation factors in human tissues and body fluids and provide an overview of their clinical utility for cancer detection, prognosis and prediction of therapeutic response to cell cycle phase specific drugs. He will also discuss the emerging concept of targeting the replication initiation machinery for cancer therapy.

Dr. Kamala Tyagarajan, (EMD-Millipore) will present data from studies performed on a novel flow cytometry platform that quantitates the action of anti-cancer compounds on apoptosis/cell death and cell cycle arrest in parallel, on a novel flow cytometry platform. She will also discuss simplified methods and assays for accurate evaluation of the cell cycle distribution and Annexin V- based apoptosis detection, caspase activation and cell death.

Register Now

Date & Time

DATE: Tuesday, June 23, 2015
TIME: 11am-12pm Eastern (8am-9am Pacific; 4pm-5pm BST; 5pm-6pm CEST)

Who Should Attend

  • Cancer biologists and discovery scientists curious about the latest developments in and relevance of the dysregulation of cell cycle to cancer progression
  • Researchers wanting to bolster their understanding of the regulation of cell cycle and apoptosis
  • Scientists interested in simplifying and improving laboratory techniques for quantitating cell cycle and apoptosis

What You Will Learn

  • Methods for studying components of DNA replication initiation machinery as targets for cancer therapeutics
  • The impact of anti-cancer compounds on cell cycle and cell death pathways
  • Preferred methods to accurately evaluate cell cycle, proliferation and apoptosi

The Presenters

Dr. Kai Stoebe

Dr. Kai Stoebe

Dr. Kai Stoeber is Vice President of Global Innovation at Shionogi Europe and is an expert in cancer cell cycles and biomarkers. Dr. Stoeber received his B.Sc. in Biological Sciences from the University of Bonn and his Ph.D. from the University of Cambridge. His Ph.D. studies in the laboratory of Ron Laskey showed that dysregulation of the DNA replication initiation machinery is a major, early event in the genesis of cancer. From 2002-2014, Stoeber was co-principal investigator of the Chromosomal Replication Group at University College London. His work there with Gareth Williams led to a new cell cycle biomarker algorithm that identifies cell cycle kinetics in dynamic tumour cell populations and predicts response to cell-cycle phase-directed chemotherapeutic agents and selected targeted therapies. Dr. Stoeber joined the Japanese pharmaceutical company Shionogi in 2014 where he identifies and evaluates new technologies as well as new targets or molecules from external sources in academia and biopharma


Dr. Kamala Tyagarajan

Dr. Kamala Tyagarajan

Dr. Kamala Tyagarajan (University of California, Berkeley) is a Senior R&D Manager at EMD Millipore, where she leads a team responsible for applications development on multiple guava easyCyte™ and Muse® cytometric platforms. Dr. Tyagarajan has extensive experience with fluorescence-based probes and technologies, as well as with the development of cell- and blood-based cytometric solutions. Prior to her work on guava easyCyte™ platforms, Kamala worked at Lynx Therapeutics, developing novel, fluorescence-based technologies for proteomics.



Dr. Gwen Taylor

Dr. Gwen Taylor

Dr. Gwen Taylor is the Senior Developmental Editor and Webinar Program Manager for Current Protocols, Wiley publishers.





Register Now

, , , ,

Comments are closed.